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A B S T R A C T
The discovery of expression of the erythropoietin receptor (EPO-R) on neoplastic cells has led to con-
cerns about the safety of treating anaemic cancer patients with EPO. In addition to its endocrine function,
the receptor may play a role in tumour progression through an autocrine mechanism. In this study, the
expression of EPO, EPO-R and platelet-derived growth factor BB (PDGF-BB) was analysed in ﬁve feline
and 13 canine osteosarcomas using immunohistochemistry (IHC) and reverse transcription polymerase
chain reaction (RT-PCR).
EPO expression was positive in all tumours by IHC, but EPO mRNA was only detected in 38% of the
canine and 40% of the feline samples. EPO-R was expressed in all samples by quantitative RT-PCR (RT-
qPCR) and IHC. EPO-R mRNA was expressed at higher levels in all feline tumours, tumour cell lines, and
kidney when compared to canine tissues. PDGF-BB expression was variable by IHC, but mRNA was de-
tected in all samples. To assess the functionality of the EPO-R on tumour cells, the proliferation of canine
and feline osteosarcoma cell lines was evaluated after EPO administration using an alamarBlue assay and
Ki67 immunostaining. All primary cell lines responded to EPO treatment in at least one of the per-
formed assays, but the effect on proliferation was very low indicating only a weak responsiveness of EPO-
R. In conclusion, since EPO and its receptor are expressed by canine and feline osteosarcomas, an autocrine
or paracrine tumour progression mechanism cannot be excluded, although in vitro data suggest a minimal
role of EPO-R in osteosarcoma cell proliferation.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Erythropoietin (EPO) is a small glycoprotein hormone which
mostly promotes erythropoiesis, but has also non-haematopoietic,
growth-promoting and apoptosis-inhibiting roles (Noguchi et al.,
2008; Debeljak et al., 2014; Wan et al., 2014). Recently, it has been
shown in a mouse model that angiogenesis in tumours is modu-
lated by inducing EPO production via platelet-derived growth factor
BB (PDGF-BB) in tumour stromal cells (Xue et al., 2012). This system
is based on a complex paracrine mechanism involving tumour cells,
stromal cells and, in particular, tumour blood vessels. In addition,
high amounts of circulating EPO have been shown to stimulate pro-
liferation, migration and cell sprouting of endothelial cells (Xue et al.,
2012).
In adults, EPO is mainly produced in the kidneys. It binds to the
erythropoietin receptor (EPO-R) and activates JAK-STAT-signalling
(Noguchi et al., 2008). EPO-R is expressed predominately on erythro-
cyte progenitors and EPO can be used therapeutically in humans
and animals to treat anaemia (Eschbach and Adamson, 1985). Human
cancer patients withmyelodysplastic disorders are frequently treated
with EPO but there is an ongoing discussion about the effect of EPO on
tumour cells. Positive effects of EPO for humans (Ludwig et al., 1994;
de Campos et al., 1995; Demetri et al., 1998; Mittelman et al., 2001;
Wallvik et al., 2002; Jädersten et al., 2008) and animals (Langston
et al., 2003) have been reported. However, several clinical studies
showed worse survival times and shorter disease-free intervals
after EPO treatment in cancer patients (Henke et al., 2003, 2006;
Leyland-Jones et al., 2005; Savonije et al., 2005; Bohlius et al., 2009).
The presence of EPO and EPO-R has been demonstrated in various
tumours in humans and animals (Acs et al., 2001; Arcasoy et al.,
2002; Batra et al., 2003; Sfacteria et al., 2005; Klopﬂeisch et al., 2012;
Rózsás et al., 2013; Reinbothe et al., 2014) and EPO has been shown
to promote angiogenesis, vessel maturity, drug resistance, prolif-
eration and tumour progression (Morais et al., 2013; Asano et al.,
2015). Others have questioned the functionality of EPO-R on tumour
cells (Sinclair et al., 2007) due to its low level of expression (Swift
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et al., 2010). In addition, treatment of EPO-R-expressing cell lines
with EPO did not enhance cell proliferation in vitro (Westphal et al.,
2002; Farrell and Lee, 2004).
Osteosarcoma is considered to be themost frequent bone tumour
in dogs and cats (Quigley and Leedale, 1983) but the metastatic
behaviour differs between the two species, with frequent distant
metastases in dogs (Spodnick et al., 1992) and a remarkably low
metastatic rate in cats (Dimopoulou et al., 2008). To our knowl-
edge, no studies about EPO and its receptor in bone tumours of cats
or dogs have been reported. Recently, PDGFs and PDGF receptors
(PDGF-R) were found to be overexpressed in canine osteosarcoma
(Xue et al., 2012; Maniscalco et al., 2013). Moreover, PDGFs and
PDGF-Rs were co-expressed, suggesting that an autocrine and/or
paracrine loop could be involved (Xue et al., 2012; Maniscalco et al.,
2013). No data about PDGFs exist in feline osteosarcomas.
We hypothesised that the expression pattern of EPO, EPO-R and
PDGF-BB in canine and feline osteosarcoma cells differs between
the two species and that this may inﬂuence tumour growth, an-
giogenesis and the different metastatic behaviour in the two species.
Materials and methods
Sample collection
Tumour samples from dogs (n = 13) and cats (n = 5) were collected after ther-
apeutic limb amputation or euthanasia. Control samples (kidney, bone marrow,
cerebellum) were obtained from animals euthanased for reasons other than osteo-
sarcoma. Material was collected from surgery (with informed owner’s consent) or
from cadaveric clinical waste and was conveyed to the Institute of Pathology of the
University of Veterinary Medicine. The study was approved by the Ethical and Animal
Welfare Committee of the University of Veterinary Medicine (15 December 2014)
and conducted in accordance with the requirements of the Austrian Act on Animal
Experiments.
Aliquots of samples were either ﬁxed in 4% buffered formaldehyde or ﬂash frozen
in liquid nitrogen with or without RNA later solution (Life Technologies).
Immunohistochemistry
For immunohistochemistry (IHC), paraﬃn sections were used and stained with
either an anti-EPO, (sc-7956, polyclonal, dilution 1:50; Santa Cruz Biotechnology),
an anti-EPO-R (C-20, sc-696, polyclonal, dilution 1:50; Santa Cruz Biotechnology),
an anti-EPO-R (M-20 sc-697, polyclonal, dilution 1:75; Santa Cruz Biotechnology)
or an anti-PDGF-BB antibody (ab21234, polyclonal, dilution 1:500; Abcam). The eval-
uation score suggested by Detre et al. (1995) was used. Speciﬁcity of the assays was
tested by immunoblotting (see Appendix: Supplementary material).
Cell culture
Commercially available canine osteosarcoma cells D-17 (LGC Standards) or primary
tumour-derived neoplastic cells (canine: COS_1186w and COS_1189; feline: FOS_1077
and FOS_1140; Lonza) were used. Cells were grown in Dulbecco’s modiﬁed eagle’s
medium (DMEM) low glucose with 10% foetal calf serum (FCS, Sigma-Aldrich) and
625 pg Amphotericin B (Bio&Sell), 2 nM glutamine (Biochrom) and 1% Pen/Strep/
Fungi Mix (Bio&Sell).
AlamarBlue test
Cells were exposed to different concentrations of EPO and proliferation was de-
termined with the alamarBlue test (Resazurin, Sigma Aldrich) to evaluate the
functionality of EPO-R as suggested previously (Levine et al., 2005; LaMontagne et al.,
2006; Laugsch et al., 2008). Brieﬂy, 2000 cells/well were seeded in ﬂat bottomed
96-well plates (Sarstedt) and supplemented with 0, 0.001, 0.01, 0.1, 1 or 10 U/mL
of alpha erythropoietin (Epoietin, Binocrit 1000 IU/0.5 mL, Sandoz) in 5 μL PBS, or
5 μL PBS alone (control) with or without 10% FCS in the medium. Cells were incu-
bated with EPO for 48 h before 10% alamarBlue was added, and the 570–600 nm
ratio was measured on a plate reader (Sunrise, Tecan).
Ki67 immunocytochemistry
For Ki67 immunocytochemical staining, 23,000 (for D-17, FOS_1077 and
FOS_1140) or 46,000 cells (for COS_1189 and COS_1186w) were seeded onto round
glass cover slides, and supplemented with 0.001, 1 or 10 U/mL alpha erythropoi-
etin (Epoietin, Binocrit, Sandoz) in 5 μL PBS or PBS alone with or without 10% FCS
in the medium. After 48 h, cells were ﬁxed in 4% formaldehyde and stained using
an anti-Ki67 antibody (clone 7B11, Life Technologies). For the analysis of Ki67 staining,
approximately 1000 cells/slide were counted and classiﬁed as stained or un-
stained to generate a percentage of positive cells.
PCR
About 30 mg of fresh frozen or RNAlater (Life Technologies)-preserved tissue or
pellets of 105–106 cultured cells were used for RNA isolation using either themiRNeasy
Mini Kit (Qiagen) or the RNeasy Fibrous Tissue Mini Kit (Qiagen). Concentration and
the RNA Integrity Number (RIN) were determined with a 2100 Bioanalyzer (Agilent
Technologies) (see Appendix: Supplementarymaterial). Using the High-Capacity cDNA
Reverse Transcription Kit (Life Technologies), 500 ng RNA/sample was transcribed
into cDNA. Feline and canine EPO and PDGF-B mRNA were detected by qualitative
dye-based PCR. Qualitative assessment was performed by melting curve analysis.
Canine EPOmRNAwasmeasuredwith a qualitative hydrolysis-probe PCR assay. Quan-
tiﬁcation of EPO-R mRNA was performed by a conventional hydrolysis probe-
based format. To compensate for technical variance, data were normalised with the
reference genes OAZ1 (De Jonge et al., 2007; Kwon et al., 2009) and the canine and
feline orthologues of human C12orf43 (Tsai and Breen, 2012).
Statistical evaluation
RT-qPCR data were analysed using REST 2009 (Qiagen). For the Ki67 and
alamarBlue assays, signiﬁcance was assessed by a linear regression model. A de-
tailed description of the statistical methods is provided in the Appendix:
Supplementary material.
Results
Immunohistochemistry
Total scores for EPO IHC ranged from 2 to 9 in feline tumours
and from 3 to 9 in canine tumours. EPO immunostaining resulted
either in a homogenous or heterogeneous pattern within the tumour
area. Cytoplasmic and nuclear staining was present (Figs. 1a, b) with
additional staining of giant cells and partial staining of endothe-
lial cells within the tumour. In the canine and feline kidney (positive
controls), tubules and collecting ducts were stained. Negative con-
trols were negative.
EPO-R IHC resulted in a cytoplasmic staining pattern (total scores
ranged from 2 to 9 in both species); a clear membrane staining was
not observed (Figs. 1c, d). No differences were found when com-
paring the C-20 and the M-20 antibodies. All negative controls were
negative.
The immunostaining pattern for PDGF-BB was considerably het-
erogeneous in the osteosarcomas of cats and dogs and total scores
ranged from 0 to 9. The staining pattern in canine and feline tumour
cells was cytoplasmic (Fig. 1e). In feline osteosarcomas a perivas-
cular distribution of positive cells was partly observed (Fig. 1f). In
addition to the tumour cells, giant cells and osteoblasts were pos-
itive for PDGF-BB immunostaining in both species. In the positive
controls (feline and canine cerebellum), neurons were stained as
expected and negative controls were unstained. IHC results are
summarised in Table 1.
Table 1
Distribution of immunohistological scores in canine and feline osteosarcomas.
Total IHC score EPO
(n = 18)
EPO-R
(n = 18)
PDGF-BB
(n = 18)
Dog Cat Dog Cat Dog Cat
0 0 0 0 0 0 1
1 0 0 0 0 2 0
2 0 1 1 1 5 1
3 2 0 4 0 3 1
4 1 2 1 1 0 0
6 7 0 5 1 3 0
9 3 2 2 2 0 2
EPO, erythropoietin; EPO-R, erythropoietin receptor; PDGF-BB, platelet-derived growth
factor BB.
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RNA expression analysis
PDGF-B mRNA was expressed in all feline (n = 5) and canine
(n = 13) samples as well as in the kidney and the bone marrow (pos-
itive controls). In contrast, EPO mRNA was detected in 38% of the
canine tumour samples and 40% of the feline osteosarcoma samples.
Four canine samples had a near-threshold level of expression, but
were graded as negative.
RT-qPCR showed that the average amount of EPO-R mRNA in
feline osteosarcomas was higher than that of dogs. The average Cq
value (±SD) for canine EPO-RmRNA (31.8 ± 1.4) was higher than that
of the feline EPO-R mRNA (26.9 ± 0.5; P ≤ 0.001; 94-fold change)
(Fig. 2). The tissue samples used as positive controls, kidney and
bone marrow, also showed this different expression level of EPO-R
mRNA between the two species. Cq values of canine EPO-R mRNA
in kidney were 27.4 ± 0.5 compared to 24.8 ± 0.8 in feline kidney
(P ≤ 0.001; 6.7-fold change). Canine bone marrow samples showed
an average Cq of 31.2 ± 0.1, whereas feline samples showed an average
Cq of 25.9 ± 1.6 (39-fold change).
Statistical analysis of bone marrow was not undertaken because
of an observed RT-qPCR inhibition in 2/4 canine samples. For each
species, the Cq values of tumour tissues were signiﬁcantly lower
compared to those in kidney and bone marrow (P ≤ 0.05). The ex-
pression patterns of primary cell cultures isolated from some of the
original osteosarcomas correlated well with those of the original
tumour tissue (Fig. 2).
In vitro EPO-R functionality assay
The effects of EPO in vitro are summarised in Figs. 3, 4. In the
absence of FCS, the feline osteosarcoma cell lines and the canine
cell line COS_1189 showed a signiﬁcant dose-dependent increase
in absorbance 2 h and 4 h after alamarBlue addition (FOS_1077: 2 h,
P = 0.03 and 4 h, P = 0.05; FOS_1140: 2 h, P < 0.01 and 4 h, P = 0.01;
COS_1189: 2 h, P < 0.01 and 4 h, P = 0.05) (Figs. 3, 4). However, the
explained variance was low ranging from 7% to 22%. In COS_1186w
cells, the absorbance decreased signiﬁcantly after 4 h (P < 0.01) but
not after 2 h (P = 0.52). In FCS supplemented medium, the D-17 cell
line showed increased proliferation after 2 h, but not after 4 h. EPO
treatment had no effect on all other cell lines.
The relative number of Ki67 positive cells was used as an alter-
native way to determine the potential growth enhancing effects of
Fig. 1. Immunohistochemical staining of canine and feline osteosarcomas. (a) Canine osteosarcoma, erythropoietin (EPO); (b) feline osteosarcoma, EPO; tumour cells and
stromal cells showed cytoplasmic and nuclear staining. (c) Canine osteosarcoma, erythropoietin receptor (EPO-R); (d) feline osteosarcoma, EPO-R; EPO-R was expressed in
tumour cells and giant cells. (e) Canine osteosarcoma, platelet-derived growth factor BB (PDGF-BB); (f) feline osteosarcoma, PDGF-BB; osteosarcoma cells showed a cyto-
plasmic granular staining pattern. In some samples a perivascular distribution was observed. Scale bar = 100 μm.
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EPO on osteosarcoma cells using EPO concentrations of 0.001 U/mL,
1 U/mL and 10 U/mL (Fig. 5). In the presence of FCS, two canine cell
lines showed a signiﬁcant increase of Ki67 positive cells (COS_1186w:
P = 0.02; COS_1189: P = 0.02). Without stimulation by FCS, the
numbers of cells for COS_1186w and COS_1189 were insuﬃcient
to determine a Ki67 index. All other set ups showed no impact of
EPO treatment.
Discussion
The potential effect of EPO on tumours has been a longstanding
debate. There are two primarymechanisms bywhich tumour growth
could be affected: either via the direct action of EPO on tumour cells
expressing a functional EPO-R or indirectly by induction of angio-
genesis. Due to the low binding eﬃciency of EPO to its receptor, these
effects should be greatly inﬂuenced by the amount of EPO present
in the target tissue (Yan and Krzyzanski, 2013). Although it is gen-
erally assumed that the kidney is the only source of EPO (Krantz,
1991), several other organs (Fried, 1972; Digicaylioglu et al., 1995;
Yasuda et al., 1998) and tumours (Suzuki et al., 2001; Batra et al.,
2003; Pollio et al., 2005; Durno et al., 2011) also secrete EPO. Serum
EPO concentrations are very similar in dogs and cats (Cook and
Lothrop, 1994).
In the current study, EPO, EPO-R and PDGF-BB were detected by
IHC in canine and feline osteosarcomas. The EPO and EPO-R
immunostaining pattern was comparable between both species. The
PDGF-BB results are in accordance with previous reports for dogs
(Maniscalco et al., 2013). The distribution of PDGF-BB in the cat was
partly perivascular in contrast to what was observed in canine
tumours. Therefore, a paracrine or autocrine role for these factors
is possible in canine and feline osteosarcomas.
The antibodies against EPO-R used in our study (M-20 and C-20)
were not generated against the canine or feline EPO-R protein. Se-
quence similarities, positive controls, peptide blocking experiments,
and their prior use on canine tissue by other groups (Sfacteria et al.,
2005) convinced us of their suitability. It is noteworthy that the speci-
ﬁcity of these commercial antibodies has been questioned (Brown
et al., 2007; Jelkmann and Laugsch, 2007; Elliott et al., 2013).Western
blotting indicated that only M-20 detects the correct band at 59 kD
(Elliott et al., 2006) while C-20 detects three unspeciﬁc bands (Elliott
et al., 2013), rendering them not suitable for IHC (Elliott et al., 2006).
A novel EPO-R-speciﬁc antibody, A82, has been developed (Swift
et al., 2010) but is currently not commercially available.
RT-PCR was used to support the IHC results. EPO-R and PDGF-B
mRNA was present in all feline and canine samples supporting the
protein data. Although EPOmRNAwas only present in less than half
of the feline and canine tumour samples, this difference could be
explained by the presence of EPO originating from the serum. This
ﬁnding supports the hypothesis that some of the sampled tumours
are capable of autocrine stimulation as shown in other tumour types
(Heldin, 2012).
Since Elliott et al. (2014) claimed that EPO-R mRNA concentra-
tion in tumours is too low to allow the receptor to be expressed on
the cell surface, quantitative RT-PCR was used to determine EPO-R
mRNA levels in canine and feline osteosarcomas. Interestingly, there
was a signiﬁcant difference in EPO-RmRNA expression between cat
and dog samples. Generally higher amounts of EPO-R mRNA were
detected in all samples (osteosarcomas, osteosarcoma-derived cells,
kidney, and bone marrow) from cats compared with dogs. The
primary feline and canine cell cultures maintained EPO-RmRNA ex-
pression and notably the expression level increased in three of four
cell lines. These results conﬁrm that osteosarcoma cells express
EPO-R.
Consistent with results from previous studies (Swift et al., 2010;
Elliott et al., 2013, 2014) the amount of EPO-R mRNA was lower in
the tumour than in the reference tissues. To explain the lack of cor-
relation between IHC results and RT-qPCR data, we should consider
that proteins are synthesised much faster and have a longer half-
life than mRNAs. Therefore, the correlation between mRNA and
protein level is generally poor (Anderson and Seilhamer, 1997; Chen
et al., 2002; Vogel and Marcotte, 2012).
Many tumours, in particular osteosarcomas, have a high level of
intratumoural heterogeneity (Vogelstein et al., 2013). Therefore, using
a small amount of homogenised tumour in PCR or Western blot
might not reﬂect the whole neoplasm (Gerlinger et al., 2012;
Raychaudhuri et al., 2012; Zhang et al., 2014), as structures other
than tumour cells (blood vessels, stroma, immune cells) will also
contribute to the quantitative results.
There is evidence that the expression of EPO-R mRNA alone is
not suﬃcient to determine its effect on cells (Swift et al., 2010).
Therefore, we used an alamarBlue assay and Ki67 immunohisto-
chemistry to test the functional effect of EPO and functionality of
EPO-R in an in vitro system. No general proliferation-enhancing effect
of EPO on canine or feline osteosarcoma cells was observed. Minimal
effects were seen in groups grown in medium without FCS supple-
mentation in the alamarBlue test or in mediumwith FCS in the Ki67
assay, indicating inﬂuences of some undeﬁned growth factors in
serum. The anti-apoptotic properties of EPO, leading to longer cell
survival in the absence of FCS, may result in higher turn-over mea-
sured in the alamarBlue assay, an effect possibly covered by the
proliferation-enhancing effects of FCS. The Ki67 assay detected
Fig. 2. Erythropoietin receptor (EPO-R) mRNA expression changes relative to the ref-
erence genes OAZ1 and C26H12orf43/CD3H12orf43 in canine and feline osteosarcomas
and reference tissues as well as in osteosarcoma cell cultures, showing a signiﬁ-
cant difference between tumours and corresponding tissues, and between canine
and feline osteosarcomas. Boxes depict 25%–75% interval, whiskers the 5%–95% in-
terval. Highest and lowest values are indicated by x. Where boxplots were
inappropriate, individual values are marked by circles (cat) or rectangles (dog).
Tumours and corresponding cell lines are marked by the same shades of grey, and
canine bone marrow samples showing inhibition are marked by light grey edging.
Signiﬁcant differences are marked by an asterisk.
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dividing cells, but not prolonged cell survival. Altogether, these results
are in accordance with those of Shiozawa et al. (2013), who re-
ported that EPO did not stimulate the growth of human prostate
cells, but protected them from apoptosis.
Conclusions
EPO, EPO-R and PDGF-BB were expressed in cat and dog osteo-
sarcomas, but no signiﬁcant differences between the two species
Fig. 3. Regression plots of canine cultured cells in the presence of erythropoietin (EPO) (0, 0.1, 0.01, 0.001, 0.0001 and 1 U/well) with or without foetal calf serum (FCS).
Regression plots for the 2 h interval are depicted in black and individual values are marked as x. The 4 h interval is depicted in grey showing the individual values as ○.
D-17 and COS_1186w cells showed a marked decrease in absorbance in the absence of FCS, but an increase in absorbance after 4 h for D-17 and after 2 h and nearing
signiﬁcance after 4 h in COS_1186w cells when FCS was added. COS_1189 cells showed an increase in absorbance after 4 h (without FCS) and 2 h and 4 h in the presence
of FCS.
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Fig. 4. Regression plots of feline cultured cells in the presence of erythropoietin (EPO) (0, 0.1, 0.01, 0.001, 0.0001 and 1 U/well) with or without foetal calf serum (FCS).
Regression plots for the 2 h interval are depicted in black and individual values are marked as x. The 4 h interval is depicted in grey showing the individual values as ○.
FOS_1077 and FCS_1140 cells showed a signiﬁcant increase in their absorbance in the presence of FCS, but not without FCS.
Fig. 5. Percentage of Ki67 positive stained feline (FOS_1077, FOS_1140) and canine (COS_1186w, COS_1189, D-17) osteosarcoma cell lines after treatment with various con-
centrations of erythropoietin (EPO) with or without foetal calf serum (FCS). NGC, negative control samples, without FCS or EPO. Circles mark the individual values, bars
depict the mean of the treatment group.
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were observed, except for EPO-R mRNA expression. These results
may suggest potential species-speciﬁc growth promoting or inhib-
iting effects of EPO on tumour cells.
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